Literature DB >> 24807046

Pruritus in cholestasis: facts and fiction.

Ulrich Beuers1, Andreas E Kremer, Ruth Bolier, Ronald P J Oude Elferink.   

Abstract

Pruritus is a common symptom in patients with cholestatic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, or hereditary pediatric cholestatic disorders and may accompany, although less frequently, many other liver diseases. Recent findings indicate that lysophosphatidic acid (LPA), a potent neuronal activator, and autotaxin (ATX; ectonucleotide pyrophosphatase/phosphodiesterase 2), the enzyme which forms LPA, may form a key element of the long-sought pruritogenic signaling cascade in cholestatic patients suffering from itch. Serum ATX, but no other pruritogen candidate studied so far, correlates with pruritus intensity and responds to therapeutic interventions. In this comprehensive review, we provide a short update on actual insights in signal transmission related to pruritus and discuss pruritogen candidates in cholestasis. We also summarize evidence-based and guideline-approved as well as experimental therapeutic approaches for patients suffering from pruritus in cholestasis.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24807046     DOI: 10.1002/hep.26909

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

Review 2.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 3.  [Intrahepatic cholestasis of pregnancy : Rare but important].

Authors:  A E Kremer; K Wolf; S Ständer
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

4.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 5.  THE SKIN MICROBIOTA AND ITCH: Is There a Link?

Authors:  Hei Sung Kim; Gil Yosipovitch
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

6.  Scale development with small samples: a new application of longitudinal item response theory.

Authors:  Carrie R Houts; Robert Morlock; Steven I Blum; Michael C Edwards; R J Wirth
Journal:  Qual Life Res       Date:  2018-02-08       Impact factor: 4.147

Review 7.  [Primary sclerosing cholangitis : Current diagnostics and treatment].

Authors:  T Liwinski; C Schramm
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

8.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

9.  Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Authors:  Minami Yagi; Atsushi Tanaka; Tadashi Namisaki; Atsushi Takahashi; Masanori Abe; Akira Honda; Yasushi Matsuzaki; Hiromasa Ohira; Hitoshi Yoshiji; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-04-16       Impact factor: 7.527

Review 10.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.